Cigna Names Brian Evanko CEO as David Cordani Transitions to Executive Chair
The Cigna Group announced a major leadership transition on February 25, 2026, appointing Brian Evanko as Chief Executive Officer effective July 1, 2026. The 49-year-old company veteran will succeed David Cordani, who will transition to the role of Executive Chair after leading the health services giant.
The Change
Evanko, who currently serves as President and Chief Operating Officer, will assume the CEO role with a compensation package that includes a $1.3 million annual base salary, a $2.6 million annual incentive target, and a $15.1 million long-term incentive target. The board also approved a one-time transitional equity award valued at $3.5 million to mark his elevation to the top position.
Cordani's transition to Executive Chair comes with adjusted compensation reflecting his new responsibilities. His annual base salary will be set at $1 million with a $2 million annual incentive target, while remaining eligible for long-term incentive awards subject to board approval.
The leadership change extends beyond the C-suite. Eric J. Foss will become Lead Independent Director effective April 1, 2026, succeeding Eric C. Wiseman, who will continue serving on the board as Chair of the Corporate Governance Committee. Evanko will also join the board as its twelfth member on April 1, ahead of his CEO appointment.
Background
Evanko brings extensive operational experience from his 13-year tenure at Cigna. His career progression demonstrates deep knowledge across multiple business segments. Since March 2025, he has served as President and Chief Operating Officer. Prior to that, he held dual roles as Executive Vice President and Chief Financial Officer of The Cigna Group while simultaneously serving as President and CEO of Cigna Healthcare from January 2024 to March 2025.
His earlier positions include Executive Vice President and CFO from January 2021 to January 2024, President of the Government Business from November 2017 to January 2021, and President of the U.S. Individual Business from August 2013 to November 2017. This diverse background spans financial management, operations, and leadership of key business units including government programs and individual insurance markets.
The succession plan represents a carefully orchestrated transition that maintains leadership continuity. By keeping Cordani as Executive Chair, Cigna ensures institutional knowledge remains at the board level while empowering new leadership to drive operational strategy.
What It Means
The planned succession signals stability and continuity for Cigna during a period of significant change in the healthcare industry. Evanko's appointment as an internal candidate suggests the board's confidence in the company's existing strategic direction and operational capabilities.
His extensive experience across Cigna's diverse business segments—from individual insurance to government programs to overall financial management—positions him to navigate the complex healthcare landscape. His recent role as COO provided direct oversight of day-to-day operations, making this a natural progression.
The company reaffirmed its 2026 financial guidance alongside the leadership announcement, projecting consolidated adjusted income from operations of at least $30.25 per share. Cigna also maintained its segment targets with Evernorth pre-tax adjusted income from operations of at least $6.9 billion and Cigna Healthcare pre-tax adjusted income from operations of at least $4.5 billion.
The compensation structure for both executives reflects market standards for healthcare industry leadership while aligning incentives with long-term performance. Evanko's long-term incentive package comprises 60% Strategic Performance Shares tied to three-year performance goals, 25% restricted stock, and 15% stock options, ensuring his interests remain aligned with shareholders.
The board restructuring, including the appointment of a Lead Independent Director and committee realignments, demonstrates governance best practices as the company prepares for this leadership transition. These changes position Cigna to maintain operational momentum while adapting to evolving healthcare market dynamics under new leadership.
*Source: SEC Form 8-K filing dated February 25, 2026*
*StockCliff Research*